Compare IMO & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMO | BDX |
|---|---|---|
| Founded | 1880 | 1897 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.2B | 54.6B |
| IPO Year | 2002 | 1998 |
| Metric | IMO | BDX |
|---|---|---|
| Price | $133.59 | $198.96 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 12 | 16 |
| Target Price | $117.60 | ★ $195.57 |
| AVG Volume (30 Days) | 477.8K | ★ 1.5M |
| Earning Date | 10-30-2026 | 11-05-2026 |
| Dividend Yield | 1.74% | ★ 2.12% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.46 | 1.59 |
| Revenue | ★ $47,078,000,000.00 | $21,840,000,000.00 |
| Revenue This Year | $32.85 | N/A |
| Revenue Next Year | $2.73 | $2.27 |
| P/E Ratio | ★ $21.25 | $124.50 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $83.27 | $140.11 |
| 52 Week High | $139.44 | $213.08 |
| Indicator | IMO | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 65.64 |
| Support Level | $120.20 | $175.60 |
| Resistance Level | $136.47 | $200.47 |
| Average True Range (ATR) | 4.61 | 3.61 |
| MACD | 0.33 | 0.37 |
| Stochastic Oscillator | 75.86 | 90.44 |
Imperial Oil Ltd is an integrated oil company active in all phases of the petroleum industry in Canada, including the exploration for, and production and sale of, crude oil, natural gas, petroleum products, and petrochemicals. It also pursues lower-emission business opportunities, including carbon capture and storage, hydrogen, lower-emission fuels, and lithium. The company's reportable segments are Upstream, Downstream, and Chemical. Maximum revenue for the company is generated from its Downstream segment, which refines crude oil into petroleum products and distributes and market these products. The Upstream segment explores and produces crude oil, its equivalents, and natural gas, and the Chemical segment manufactures and markets hydrocarbon-based chemicals and chemical products.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.